Search clinical trials for: VX 478

Total 432 results

Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Tibotec BVBA

Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Hepatitis C
Tibotec BVBA

Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Kidney Diseases | Hepatitis C
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Desipramine

In Development for Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 and Rifampin in Healthy Male Subjects

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of Telaprevir in Subjects With Hepatic Impairment

Hepatic Insufficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Completed

VX-950 and Peginterferon for Hepatitis C

Hepatitis C

Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Poland, Croatia, Russian Federation, Bulgaria, Czech Republic, Former Serbia and Montenegro, Slovakia, Slovenia, Ukraine
Vertex Pharmaceuticals Incorporated

Completed

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Bulgaria, Croatia, Former Serbia and Montenegro, Poland, Russian Federation, Slovenia
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Psoriasis
GlaxoSmithKline

Unknown

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

HIV Infections

United States
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

Hypertension

France
Boehringer Ingelheim

Completed

Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region

Pulmonary Disease, Chronic Obstructive

Croatia, Poland, Romania, Russian Federation, Slovakia, Slovenia
Boehringer Ingelheim

Completed

TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Hypertension

Belgium
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Atrial Fibrillation

Germany

Search clinical trials for: VX 478

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations